Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as "ROS1" as it appears?

With the use of real-time PCR for EGFR and of the D5F3 immunochemistry for ALK, almost 95% of our samples tested had interpretable results as compared to around 82% with the initially used techniques. Since EGFR mutations and ALK rearrangements are mutually exclusive, we currently expect one of ever...

Full description

Saved in:
Bibliographic Details
Published inLung India Vol. 34; no. 5; pp. 405 - 408
Main Author Singh, Navneet
Format Journal Article
LanguageEnglish
Published India Medknow Publications and Media Pvt. Ltd 01.09.2017
Medknow Publications & Media Pvt. Ltd
Medknow Publications & Media Pvt Ltd
Wolters Kluwer Medknow Publications
Subjects
Cancer therapies
Chemotherapy
Clinical medicine
Deoxyribonucleic acid
DNA
Epidermal growth factor
Females
Lung cancer
Lymphoma
Metastasis
Mutation
Online AccessGet full text

Cover

More Information
Summary:With the use of real-time PCR for EGFR and of the D5F3 immunochemistry for ALK, almost 95% of our samples tested had interpretable results as compared to around 82% with the initially used techniques. Since EGFR mutations and ALK rearrangements are mutually exclusive, we currently expect one of every two females with advanced/metastatic lung adenocarcinoma tested to be a candidate for targeted therapy (37% EGFR and 13% ALK prevalence in our setting). [...]for 100 lung cancer patients presenting to the clinic, the actual statistics turn out to be as shown in [Table 1]. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, open-label, phase 3 study.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:0970-2113
0974-598X
DOI:10.4103/lungindia.lungindia_305_17